Which one is more effective, filgrastim or lenograstim, during febrile neutropenia attack in hospitalized patients with solid tumors?
BACKGROUND
Chemotherapy-induced febrile neutropenia (FN) with solid tumors causes mortality and morbidity at a significant rate. The purpose of this study was to compare the effects of filgastrim and lenograstim started with the first dose of antibiotics in hospitalized patients diagnosed with FN.


METHODS
Between February 2009 and May 2012, 151 patients diagnosed with FN were evaluated, retrospectively. In those considered appropriate for hospitalization, convenient antibiotic therapy with granulocyte colony stimulating factors was started within first 30 minutes by completing necessary examinations in accordance with FEN guide recommendations.


RESULTS
In this study, 175 febrile neutropenia attacks in 151 patients were examined. Seventy three of the patients were male and 78 were female. The average age was 53.6 and 53.6, respectively. The most common solid tumor was breast carcinoma in 38 (25%) . One hundred and five FN patients (58%) were those who received granulocyte colony stimulating factors as primary prophylaxis.


CONCLUSIONS
While studies comparing both drugs generally involve treatments started for prophylaxis, this study compared the treatment given during the febrile neutropenia attack. Compared to lenograstim, filgastrim shortens the duration of hospitalization during febrile neutropenia attack by facilitating faster recovery with solid tumors.
Department of Medical Oncology, Yeditepe University Hospital, Turkey E-mail : dr.ozlemus@gmail.com.
Ozlem Uysal
OU
Sonmez
Ertugrul
E
Guclu
Ummugul
U
Uyeturk
Onur
O
Esbah
Ibrahim
I
Turker
Oznur
O
Bal
Burcin
B
Budakoglu
Ulku Yalcintas
UY
Arslan
Oguz
O
Karabay
Berna
B
Oksuzoglu
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D000069585:Filgrastim / Q000627:therapeutic use*; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006401:Hematologic Agents / Q000627:therapeutic use; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies
D000276:Adjuvants, Immunologic; D006401:Hematologic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D000069585:Filgrastim